United Kingdom (UK)
Recombinant monoclonal antibody to OPGL. Manufactured using AbAb’s Recombinant Platform with variable regions (i.e. specificity) from the hybridoma 18B2.
UniProt Accession Number of Target Protein: O14788
Alternative Name(s) of Target: CD254; Tumor necrosis factor ligand superfamily member 11; TNFSF11; TNF superfamily member 11; Osteoclast differentiation factor; ODF; Osteoprotegerin ligand; OPGL; OPTB2; Receptor activator of nuclear factor kappa-B ligand; RANKL; hRANKL2; TNF-related activation-induced cytokine; TRANCE; sOdf; TNLG6B
Immunogen: The original antibody was generated by immunizing transgenic HuMab mice with purified recombinant OPGL derived from E. coli or CHO cells. Sera from immunized mice were tested for antibody binding to OPGL.
Specificity: This antibody is specific for human OPGL. In vivo experiments have shown cross reactivity with Cynomolgus Monkey OPGL.
Application Notes: The binding affinity of this antibody's original format (human IgG1) to hOPGL was confirmed by ELISA. Its binding kinetics to hOPGL 140 and hOPGL 158 was measured by SPR analysis; a KD of 0.211 nM was measured for hOPGL 140. This antibody was evaluated for its neutralizing activity against osteoclast formation induced by Osteoprotegerin ligand (OPGL) using RAW 264.7 cells, as measured by tartrate-resistant acid phosphatase (TRAP) activity; it inhibited osteoclast formation in a dose-dependent manner with an IC50 of 80 ng/ml. This antibody's pharmacokinetics and in vivo activity were assessed in cynomolgus monkeys — three female cynomolgus monkeys (not greater than five years of age, each weighing between 2 to 5 kgs) received a single subcutaneous dose of 1 mg/kg; serum samples were collected over 56 days to determine the levels of the antibody and analyze bone turnover markers such as serum N-telopeptide (serum N-Tx). The antibody's levels in the serum declined slowly over the testing period; the last measurement on day 56 showed a serum concentration of ~100 ng/ml. Serum N-Tx levels were greatly reduced compared to baseline immediately following injection (~minus 60%), further decreased to a minimum of ~minus 75% over a period of two weeks, after which they began to increase gradually but remained lower in a statistically significant manner than baseline with a final measurement of ~minus 25% on day 56 (US7718776B2).
Antibody first published in: PMID: